Sort by
Refine Your Search
-
Listed
-
Category
-
Program
-
Employer
- University of Basel
- Empa
- ETH Zürich
- Paul Scherrer Institut Villigen
- University of Zurich
- Academic Europe
- Swiss Federal Institute for Forest, Snow and Landscape Research WSL
- CERN - European Organization for Nuclear Research
- EPFL
- European Magnetism Association EMA
- Fluxim AG
- Prof. Dr. Ricarda Toerner
- University of Applied Sciences Northwestern Switzerland
- Zürcher Hochschule für Angewandte Wissenschaft ZHAW
- École Polytechnique Fédérale de Lausanne (EPFL)
- 5 more »
- « less
-
Field
-
learning with the physics of laser–matter interaction. Your developments will be directly validated through multiple experimental runs on state-of-the-art laser processing equipment. You will work closely
-
data identifying the most resilient and high-performing plant species. Measurements and analyses will be conducted at multiple sites across the EU and integrated with soil-plant-atmosphere modeling
-
Ideas, SBB, and gfs.bern, you will collaborate with Dr. Andrea Bublitz to develop and validate LLM-assisted pipelines that reduce data-collection costs while maintaining validity for marketing and opinion
-
welds. Modelling and simulation: development of a physics-based simulation framework (e.g., phase-field modelling) to predict hydrogen-assisted crack growth and long-term mechanical integrity of steels
-
research on synthetic data. In an Innosuisse project with Boomerang Ideas, SBB, and gfs.bern, you will collaborate with Dr. Andrea Bublitz to develop and validate LLM-assisted pipelines that reduce data
-
discovery and development through in vitro modelling of in-patient conditions in order to address antibiotic resistance, a problem of global importance. To reach this goal, AntiResist has assembled a panel of
-
. Empa is a research institution of the ETH Domain. Empa’s Laboratory of Biomimetic Membranes and Textiles develops novel smart fibers, textiles and membranes for body monitoring, drug delivery and tissue
-
disease and to develop pioneering therapies benefiting the lives of patients in areas of unmet need. With more than 70 research groups and 800 employees, the Department of Biomedicine is the largest
-
disease and to develop pioneering therapies benefiting the lives of patients in areas of unmet need. With more than 70 research groups and 800 employees, the Department of Biomedicine is the largest
-
discovery and development through in vitro modelling of in-patient conditions in order to address antibiotic resistance, a problem of global importance. To reach this goal, AntiResist has assembled a panel of